title: [Outcome and Problems of Nab-Paclitaxel Therapy for Gastric Cancer in Clinical Practice].
abstract: Nanoparticle albumin-bound paclitaxel(nab-PTX)was approved for the treatment of gastric cancer without a large-scale clinical trial in Japan. Its safety and efficacy should be validated in clinical practice. We retrospectively investigated prognostic factors related to time to treatment failure(TTF)in 11 patients with unresectable or recurrent gastric cancer treated with nab- PTX in our hospital. In univariate analysis, Onodera's prognostic nutritional index(PNI)and the time from the start of first-line chemotherapy to the start of nab-PTX were related to TTF. In multivariate analysis, Onodera's PNI was identified as an independent predictive factor for TTF (hazard ratio 0.056, p=0.022). PNI could contribute to adequate patient selection and the improvement of nab-PTX therapy efficacy ingastric cancer.
authors.affiliation: Dept. of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine.
authors.forename: Toshifumi
authors.initials: T
authors.lastname: Doi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Okayama
authors.forename: Osamu
authors.initials: O
authors.lastname: Dohi
authors.forename: Naohisa
authors.initials: N
authors.lastname: Yoshida
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kamada
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Katada
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Sogame
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Uchiyama
authors.forename: Osamu
authors.initials: O
authors.lastname: Handa
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Takagi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Yasuda
authors.forename: Junichi
authors.initials: J
authors.lastname: Sakagami
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Konishi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Naito
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Itoh
mesh_terms: D000368:Aged; D000418:Albumins / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: C520255:130-nm albumin-bound paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel